Asthma Management Guidelines

Classification and Diagnosis

The National Asthma Education and Prevention Program (NAEPP) guidelines recommend classifying asthma based on daytime symptoms and rescue inhaler use, with mild persistent asthma defined as symptoms ≥2 days per week and rescue inhaler use >2 days per week 1, 2, 3
The American Academy of Allergy, Asthma, and Immunology (AAAAI) suggests that nighttime awakenings are a key factor in distinguishing between mild and moderate persistent asthma, with none indicating mild persistent asthma 1

The American College of Allergy, Asthma, and Immunology (ACAAI) recommends daily low-dose inhaled corticosteroid (ICS) plus as-needed short-acting beta-agonist (SABA) for quick relief as the preferred treatment for mild persistent asthma 2, 3, 4
The NAEPP guidelines conditionally recommend either daily low-dose ICS with as-needed SABA or as-needed ICS and SABA used concomitantly for mild persistent asthma in patients ≥12 years 2, 3
The Global Initiative for Asthma (GINA) suggests initiating daily low-dose ICS as the cornerstone controller therapy, with SABA continued as needed for symptom relief 1, 2, 3, 4

The American Thoracic Society (ATS) recommends assessing medication adherence, inhaler technique, and environmental triggers before prescribing controller therapy 5, 6, 2, 3, 4
The European Respiratory Society (ERS) suggests that poor inhaler technique significantly reduces medication effectiveness, and environmental control measures should be implemented concurrently 4, 1, 2, 3

The AAAAI recommends considering leukotriene receptor antagonists (LTRAs), cromolyn, or nedocromil as alternative options if ICS is not tolerated, although LTRAs have a black-box warning for montelukast 1, 2, 3
The ACAAI suggests that theophylline may be considered, but requires monitoring due to its adverse effect profile 1, 2

The NAEPP guidelines recommend reassessing asthma control in 2-6 weeks after initiating ICS therapy, evaluating frequency of daytime symptoms, SABA use, nighttime awakenings, and interference with normal activities 2, 3, 4
The GINA suggests monitoring peak flow measurements if previously established, and considering stepping down therapy if asthma is well-controlled for ≥3 consecutive months 2, 3, 4, 7

The ATS recommends avoiding the critical error of failing to initiate controller therapy when SABA use exceeds 2 days per week, indicating inadequate asthma control and increased risk of exacerbations 1, 2, 3, 4
The ERS suggests instructing patients to rinse their mouth with water without swallowing after each ICS dose to reduce the risk of oral candidiasis 7